Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
- Conditions
- Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow Biopsy
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 10
- Registration Number
- NCT04203316
- Locations
- πΊπΈ
Children's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈArkansas Children's Hospital, Little Rock, Arkansas, United States
πΊπΈChildren's Hospital Colorado, Aurora, Colorado, United States
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery
- Conditions
- Recurrent Desmoid FibromatosisDesmoid FibromatosisUnresectable Desmoid Fibromatosis
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Magnetic Resonance ImagingOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationProcedure: X-Ray Imaging
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 35
- Registration Number
- NCT04195399
- Locations
- πΊπΈ
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
πΊπΈChildren's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈUSA Health Strada Patient Care Center, Mobile, Alabama, United States
Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia
- Conditions
- Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 16
- Registration Number
- NCT04158739
- Locations
- πΊπΈ
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
πΊπΈChildren's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈChildren's Hospital Los Angeles, Los Angeles, California, United States
Inherited Genetic Susceptibility in Langerhans Cell Histiocytosis (LCH)
- Conditions
- Histiocytosis, Langerhans-Cell
- Interventions
- Other: Biospecimen CollectionOther: Laboratory Biomarker AnalysisOther: Questionnaire Administration
- First Posted Date
- 2019-09-24
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 647
- Registration Number
- NCT04100408
- Locations
- πΊπΈ
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study
- Conditions
- Hematopoietic and Lymphoid Cell NeoplasmMalignant Solid Neoplasm
- Interventions
- Other: Educational InterventionDevice: FitBitOther: Goal SettingOther: Health Promotion and EducationOther: Media InterventionBehavioral: Telephone-Based Intervention
- First Posted Date
- 2019-09-13
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 384
- Registration Number
- NCT04089358
- Locations
- πΊπΈ
USA Health Strada Patient Care Center, Mobile, Alabama, United States
πΊπΈBanner Children's at Desert, Mesa, Arizona, United States
πΊπΈKaiser Permanente Downey Medical Center, Downey, California, United States
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Conditions
- Testicular LeukemiaB Lymphoblastic LymphomaB Acute Lymphoblastic LeukemiaMixed Phenotype Acute LeukemiaCentral Nervous System Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Bone ScanProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Positron Emission Tomography
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 4997
- Registration Number
- NCT03959085
- Locations
- πΊπΈ
Children's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈUSA Health Strada Patient Care Center, Mobile, Alabama, United States
πΊπΈProvidence Alaska Medical Center, Anchorage, Alaska, United States
Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia
- Conditions
- Central Nervous System NeoplasmInfantile FibrosarcomaRecurrent Acute LeukemiaRefractory Acute LeukemiaSolid Neoplasm
- Interventions
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 31
- Registration Number
- NCT03834961
- Locations
- πΊπΈ
Children's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈArkansas Children's Hospital, Little Rock, Arkansas, United States
πΊπΈKaiser Permanente Downey Medical Center, Downey, California, United States
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
- Conditions
- Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Interventions
- Procedure: Biospecimen CollectionOther: Drug WithdrawnOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 110
- Registration Number
- NCT03817398
- Locations
- πΊπΈ
Children's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈUSA Health Strada Patient Care Center, Mobile, Alabama, United States
πΊπΈBanner Children's at Desert, Mesa, Arizona, United States
Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma
- Conditions
- High Risk NeuroblastomaRefractory NeuroblastomaRecurrent Neuroblastoma
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 94
- Registration Number
- NCT03794349
- Locations
- πΊπΈ
Children's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈArkansas Children's Hospital, Little Rock, Arkansas, United States
πΊπΈKaiser Permanente Downey Medical Center, Downey, California, United States
Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)
- Conditions
- Lymphoblastic LymphomaT-cell LymphomaT-cell LeukemiaAcute LeukemiaRecurrent DiseaseLeukemia, Lymphocytic
- Interventions
- First Posted Date
- 2019-01-03
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 12
- Registration Number
- NCT03792256
- Locations
- πΊπΈ
Children's Hospital of Alabama, Birmingham, Alabama, United States
πΊπΈLoma Linda University Medical Center, Loma Linda, California, United States
πΊπΈChildren's Hospital of Orange County, Orange, California, United States